Comment by Guthur

This is a failure of leadership to ensure that a quality product is being delivered by the system they're responsible for.

I'd usually be pretty forgiving especially when there is a high degree of novelty.

Maybe this particular vaccine is novel and that benefit of the doubt should be extended in this case, I'm not sure though.

It's also possible this is common variation but we never hear about it.